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Abstract Alternative temozolomide regimens have been
proposed to overcome O6-methylguanine-DNA methyl-
transferase mediated resistance. We investigated the efficacy
and tolerability of 1 week on/1 week off temozolomide
(ddTMZ) regimen in a cohort of patients treated with ddTMZ
between 2005 and 2011 for the progression of a glioblastoma
during or after chemo-radiation with temozolomide or a
recurrence of another type of glioma after radiotherapy and
at least one line of chemotherapy. Patients received ddTMZ
at 100–150 mg/m2/d (days 1–7 and 15–21 in cycles of
28-days). All patients had a contrast enhancing lesion on
MRI and the response was assessed by MRI using the RANO
criteria; complete and partial responses were considered
objective responses. Fifty-three patients were included. The
median number of cycles of ddTMZ was 4 (range 1–12).
Eight patients discontinued chemotherapy because of tox-
icity. Two of 24 patients with a progressive glioblastoma had
an objective response; progression free survival at 6 months
(PFS-6) in glioblastoma was 29%. Three of the 16 patients
with a recurrent WHO grade 2 or 3 astrocytoma or oligo-
dendroglioma or oligo-astrocytoma without combined 1p
and 19q loss had an objective response and PFS-6 in these
patients was 38%. Four out of the 12 evaluable patients with a
recurrent WHO grade 2 or 3 oligodendroglioma or oligo-
astrocytoma with combined 1p and 19q loss had an objective
response; PFS-6 in these patients was 62%. This study
indicates that ddTMZ is safe and effective in recurrent gli-
oma, despite previous temozolomide and/or nitrosourea
chemotherapy. Our data do not suggest superior efficacy of
this schedule as compared to the standard day 1–5 every
4 weeks schedule.
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Introduction
Gliomas are the most common primary brain tumors in adults
and are usually classified and graded according to the World
Health Organisation (WHO). Currently, chemotherapy is
standard of care for all diffuse gliomas, either at first diag-
nosis or at first recurrence [1–5]. The most frequently used
agents are temozolomide (TMZ) and nitrosoureas. Treatment
options for patients failing radiotherapy and a first line of
alkylating or methylating chemotherapy are limited. The
cytotoxic effect of TMZ is mediated primarily via methyla-
tion at the O6 position of guanine. One of the main mecha-
nisms of tumor resistance to TMZ is thought to be mediated
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by O6-methylguanine-DNA methyltransferase (MGMT) [6].
Evidence supporting this role of MGMT comes from clinical
studies indicating that hypermethylation of the promoter of
MGMT is associated with improved tumor response and
survival in patients with GBM [7, 8]. Because of the more
continuous exposition with ddTMZ it has been assumed that
dose dense temozolomide (ddTMZ) schedules could over-
come MGMT dependent resistance against TMZ by a more
effective depletion of deplete intracellular levels of the DNA
repair enzyme, MGMT [9]. Studies using ddTMZ show it is
well tolerated and generally safe, also when given in higher
monthly doses and in patients who have previously received
TMZ [10–18]. We used the 1 week on/1 week off TMZ
regimen (ddTMZ) for patients with relapsing GBM or other
glioma after prior TMZ or nitrosourea chemotherapy to study
the efficacy and toxicity of ddTMZ in heavily pre-treated
patients with high-grade glioma.
Materials and methods
Data of all diffuse glioma patients treated with ddTMZ
after prior chemotherapy in our center were retrospectively
collected. The study was approved by the local institutional
review board. Patients were included in this study if they
had a histologically confirmed low-grade glioma or high-
grade glioma, with a progressive and measurable enhanc-
ing tumor on the MRI (diameter [2 cm), relapsing after
prior radiotherapy and at least one line of chemotherapy,
and had concluded RT at least 3 months prior to the
diagnosis of progression. We collected data about patient
characteristics, tumor characteristics, prior treatment,
number of ddTMZ cycles, use of dexamethason, adverse
effects, reason of discontinuation, and further treatments.
According to histology three categories of patients were
distinguished: patients treated with ddTMZ for a progres-
sive primary GBM after radiotherapy and TMZ (group A);
patients with recurrent astrocytoma WHO grade 2 or 3
(group B), or recurrent oligo-astrocytoma WHO grade 2 or
3, without 1p and 19q loss; and patients with progressive
WHO grade 2 or 3 oligodendroglioma or oligo-astrocytoma
with 1p and 19q loss (group C). WHO grade 2 tumors were
combined with WHO grade 3 tumors because all patients
had contrast enhancing lesions on the MRI scan at the time
of treatment with ddTMZ, suggesting malignant dediffer-
entiation of the WHO grade 2 tumors. Furthermore, a
previous study with TMZ in recurrent WHO grade 2
astrocytoma, with enhancement on the MRI-scan, at our
institution has shown similar results to the pilot trial of
TMZ in recurrent WHO grade 3 gliomas (PFS at
12 months 25% vs. 24%). [3, 4].
Patients received TMZ on day 1–7 and on day 15–21 of
a 28-day cycle for up to 12 cycles or until documented
disease progression or unacceptable toxicity. The starting
dose of the TMZ was 100 mg/m2/day. In the absence of
toxicity or only CTCAE grade 1 toxicity during the first
two treatment weeks the dose was escalated, in two steps to
dose level 1 (150 mg/m2/day; Table 1 for dose levels).
Toxicity was evaluated according to the Common Termi-
nology Criteria for Adverse Events (CTCAE; version 3.0).
In case of hematological toxicity grade 4 or non-hemato-
logical toxicity grade 3, the dosage TMZ of the next cycle
was reduced with 1 dose level. In case of CTCAE grade 4
non-hematological toxicity, the patient stopped treatment.
In case of a grade 4 hematological toxicity or a grade 3
non-hematological toxicity at dose level 4 (75 mg/m2/day),
the patient went off treatment. In case of dose reductions,
dose re-escalation was not allowed. Blood examinations
were done on day 15 and day 29 and when platelets were
above 100*109/l and neutrophils counts above 1.5*109/l,
the following 7 days TMZ was administered. Otherwise
treatment was postponed until recovery to BCTCAE
grade 1 and/or platelets were above 100*109/l. The treat-
ment was stopped if it had to be postponed for more than
2 weeks.
The objectives of the study were the assessment of
progression free survival at 6 (PFS-6) and 12 (PFS-12)
months, objective response rate (ORR), overall survival
(OS), and toxicity. OS was calculated from the start of the
TMZ treatment to the date of death. PFS was calculated
from the start of the TMZ until the date of progression or
death. Response was assessed using RANO criteria [19,
20]. Both complete and partial responses were considered
objective responses. Clinical evaluation was done every
4 weeks and MRI was made every 12 weeks or in case of
neurological deterioration. Response to treatment was
reviewed as part of this analysis (W.T.). In this explor-
atory analysis, no adjustments were made for multiple
testing.
Results
Between June 2005 and June 2011, 53 patients were treated
with ddTMZ for the progression of a glioma in our center.
Twenty-four patients were treated for a recurrent GBM
(group A), 16 patients were treated for a recurrence of a
Table 1 Dose levels of dose dense temozolomide
Dose
level
Daily temozolomide
dose (mg/m2/day)
Dose temozolomide
per cycle (mg/m2)
1 150 2100
2 125 1750
3 100 1400
4 75 1050
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WHO grade 2 or 3 astrocytoma, oligodendroglioma, or
oligo-astrocytoma, without combined 1p and 19q loss, with
a contrast enhancing lesion on MRI (group B) and 13
patients were treated for a recurrence of a WHO grade 2 or
3 oligodendroglioma or oligo-astrocytoma with combined
1p and 19q loss, with a contrast enhancing lesion on MRI
(group C). Tables 2 and 3 show the patient characteristics
of the 53 patients. All GBM patients progressed after
chemo-irradiation with TMZ, except for one patient who
had progression after radiotherapy and during the 6th cycle
of 1st line standard day 1–5 every 4 weeks schedule TMZ
chemotherapy. Five GBM patients treated with chemo-
Table 2 Characteristics of
patients treated with dose dense
temozolomide for a progressive
glioma after radiotherapy and
1 or 2 lines of chemotherapy
WHO World Health
Organisation, PS Performance
Score
Group A patients with recurrent
primary glioblastoma, Group B
patients with recurrent WHO
grade 2 or 3 astrocytoma or
oligodendroglioma or
oligoastrocytoma without
combined 1p and 19q loss and
with a contrast enhancing lesion
on MRI, Group C patients with
recurrent WHO grade 2 or 3
oligodendroglioma or
oligoastrocytoma with
combined 1p and 19q loss and
with a contrast enhancing lesion
on MRI
Characteristic All patients
No. (%)
of patients,
n = 53
Group A
No. (%)
of patients,
n = 24
Group B
No. (%)
of patients,
n = 16
Group C
No. (%)
of patients,
n = 13
Age, years
Median 49 52 43 44
Range 31–74 31–74 32–61 33–60
Sex
Male 38 (72%) 14 (58%) 13 (81%) 11(85%)
Female 15 (28%) 10 (42%) 3 (19%) 2 (15%)
First symptom
Epilepsy 36 (68%) 11 (46%) 13 (81%) 12 (92%)
Other 17 (32%) 13 (54%) 3 (19%) 1 (8%)
WHO-PS
0 15 (28%) 6 (25%) 5 (31%) 4 (31%)
1 27 (51%) 16 (67%) 7 (44%) 4 (31%)
2 11 (21%) 2 (8%) 4 (25%) 5 (38%)
WHO histology grade at first operation
2 10 (63%) 6 (46%)
3 6 (37%) 7 (54%)
Table 3 Previous treatments of
patients treated with dose dense
temozolomide for a progressive
glioma after radiotherapy and
1 or 2 lines of chemotherapy
ddTMZ dose dense
temozolomide, RT radiotherapy
Group A patients with recurrent
primary glioblastoma, Group B
patients with recurrent WHO
grade 2 or 3 astrocytoma or
oligodendroglioma or
oligoastrocytoma without
combined 1p and 19q loss and
with a contrast enhancing lesion
on MRI, Group C patients with
recurrent WHO grade 2 or 3
oligodendroglioma or
oligoastrocytoma with
combined 1p and 19q loss and
with a contrast enhancing lesion
on MRI
Characteristic All patients
No. (%) of
patients,
n = 53
Group A
No. (%) of
patients,
n = 24
Group B
No. (%) of
patients,
n = 16
Group C
No. (%) of
patients,
n = 13
ddTMZ as 2nd line of chemotherapy 40 (75%) 19 (79%) 11 (69%) 10 (77%)
ddTMZ as 3nd line of chemotherapy 13 (25%) 5 (21%) 5 (31%) 3 (23%)
Second operation 15 (28%) 3 (13%) 6 (38%) 6 (46%)
Third operation 1 (2%) 0 0 1 (8%)
Time between start last RT and start
ddTMZ, median (range) in months
24 (5–197) 19 (8–75) 18 (5–197) 45 (10–93)
Time between last chemotherapy and
start ddTMZ, median (range)
in months
10 (0–94) 5 (0–67) 13 (1–92) 17 (1–94)
Prior 1st line treatment 53 (100%) 24 (100%) 16 (100%) 13 (100%)
RT/TMZ 27 (51%) 23 (96%) 3 (19%) 1 (8%)
TMZ 6 (11%) 1 (4%) 5 (31%) 0
PCV 20 (38%) 0 8 (50%) 12 (92%)
Prior 2nd line treatment 13 (25%) 5 (21%) 5 (31%) 3 (23%)
RT/TMZ 1 (2%) 0 1 (6%) 0
TMZ 5 (9%) 0 3 (19%) 2 (15%)
PCV 2 (4%) 0 1 (6%) 1 (8%)
Other 5 (9%) 5 (21%) 0 0
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irradiation progressed directly after six cycles of adjuvant
TMZ; all other patients had a TMZ free interval, before the
start of ddTMZ. Six patients with a recurrent primary-
GBM received a second line of therapy after chemo-irra-
diation: dendritic-cell therapy (1), cediranib (1), lomustine
combined with cediranib (2), and, imatinib combined with
hydroxyurea (2).
The median number of cycles of ddTMZ was 4 (range
1–12), three patients completed 12 cycles. Most patients
stopped because of tumor progression. One patient stopped
because of unrelated cholecystitis and elevated transami-
nases. Eight patients discontinued ddTMZ because of
toxicity: grade 4 thrombocytopenia (1), persistent grade 2
or grade 3 fatigue (5), grade 3 elevated transaminases (1),
and grade 3 allergic skin reaction (1). Five patients who
stopped because of fatigue continued TMZ in regular
regimen of day 1–5 in a 28 day cycle and tolerated this
well. In 25 patients, CD4? lymphocytes counts were
monitored; 14 (56%) of these patients developed a grade 3
CD4? lymphopenia (\0.2*109/l) and 6 (24%) of these
patients developed a grade 4 CD4? lymphopenia
(\0.05*109/l). All patients with grade 3/4 CD4? lym-
phopenia received prophylactic cotrimoxazol. None of
these patients developed a pneumocystis carinii pneumo-
nia. Two of the patients with a grade 4 CD4? lymphopenia
developed a pneumocystis carinii pneumonia, prior to
routine monitoring of CD4? counts, from which they fully
recovered.
Fifty-two patients were evaluable for response. In the
patient with cholecystitis, no follow-up imaging was done.
The PFS-6, the ORR (complete and partial response) and
median OS for the three groups of patients are shown in
Table 4. The median interval (and range) between the prior
chemotherapy and the start of the ddTMZ was 5 months
(0–67 months) in group A, 12.5 months (range 1–92) in
group B and 17 months (range 1–94) in group C. The
patients without 1p and 19q loss (group A and B) that
started with the ddTMZ within 3 months of the previous
chemotherapy (12 out of 40 patients) had a lower PFS-6
compared to the patients with a chemotherapy free interval
of more than 3 months (PFS-6 8% vs. 43%; Fisher exact
test 0.033).
Discussion
In this group of 53 chemotherapy and radiotherapy pre-
treated gliomas, ddTMZ showed activity. Although this is a
retrospective study with a limited sample size, our results
are also comparable to other studies on dose-dense TMZ in
recurrent gliomas [12–17].
However, in all our groups the observed activity is well
within the range of previous reports on standard dosing
TMZ. The PFS-6 of 29% (95%-CI 11–47%) (Table 4; group
A) in GBM is within the range of the pivotal standard dose
phase II TMZ trials in recurrent GBM. (PFS-6: 19–24%)
[21–23] More in particular, Brandes et al. described a 24%
(95% CI 14–42%) for 2nd line standard dosing TMZ in
recurrent GBM. The results in group B (recurrent WHO
grade 2 or 3 astrocytoma or oligodendroglioma without 1p
and 19q loss) are comparable to the 2nd line results in the
pivotal phase 2 trial in recurrent anaplastic astrocytoma or
anaplastic oligo-astrocytoma (PFS-6 44% versus PFS-6 38%
in the present series, Table 4) [4].
The PFS-6 in group B and C (All recurrent non-primary
GBM’s, with a contrast enhancing lesion on MRI at the
start of the ddTMZ) is higher than the PFS-6 found in the
EORTC study 26972 in recurrent oligodendroglioma, with
or without combined 1p/19q loss after first line chemo-
therapy (Table 4: PFS-6 38–62% vs. 29%), although the
PFS-12 is comparable (Table 4: PFS-12 13–15% vs. 11%)
[24]. Data on second line TMZ in recurrent oligoden-
droglial tumors with combined 1p/19q loss are scarce,
Kouwenhoven et al. [25] reported only one responder in
nine patients treated after prior procarbazine, lomustine,
and vincristine chemotherapy, but PFS-6 was not reported.
Almost none of the patients with a primary GBM or
WHO grade 2 or 3 glioma without combined 1p/19q loss
(group A and B) with a chemotherapy free interval of
3 months or less before the start of the ddTMZ had a good
outcome (PFS-6 8% vs. 43%; Fisher exact test 0.033).
Similar to the results of Perry et al. [10] on metronomic
TMZ, ddTMZ is not effective in patients with progressive
disease within 3 months of previous chemotherapy. The
patients with a dedifferentiated glioma with combined 1p/
19q loss were left out of this analysis, because these
Table 4 Outcome of patients treated with dose dense temozolomide
for a progressive glioma after radiotherapy and 1 or 2 lines of
chemotherapy
Outcome All patients
n = 53
Group A
n = 24
Group B
n = 16
Group C
n = 13
PFS-6 40% 29% 38% 62%
PFS-12 13% 13% 13% 15%
Median OS 9 months 6 months 9 months 19 months
CR ? PR 17% 8% 19% 33% (4:12)
PFS-6 progression free survival at 6 months, PFS-12 progression free
survival at 12 months, OS overall survival, CR complete response, PR
partial response
Group A patients with recurrent primary glioblastoma, Group B
patients with recurrent WHO grade 2 or 3 astrocytoma or oligoden-
droglioma or oligo-astrocytoma without combined 1p and 19q loss
and with a contrast enhancing lesion on MRI, Group C patients with
recurrent WHO grade 2 or 3 oligodendroglioma or oligo-astrocytoma
with combined 1p and 19q loss and with a contrast enhancing lesion
on MRI
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patients have a completely different prognosis and
response to chemotherapy and only two patients in this
group had progressive disease within the 3 months before
the start of the ddTMZ. The single patient relapsing during
standard TMZ and responding to ddTMZ had a progression
free survival of 48 months up till now, suggesting he didn’t
have real tumor progression at the time of ddTMZ. Prob-
ably the enhancement on MRI in this patient was caused by
radionecrosis 45 months after RT. Since all patients started
ddTMZ relatively long after (chemo-)irradiation (median
time between start last RT and start ddTMZ 24 months,
range 5–197; Table 3), it is unlikely that pseudoprogres-
sion played a role in this study [26].
Dose dense TMZ appears more toxic than the standard
dosing regimen of TMZ. Five patients were switched to the
standard day 1–5 every 4 weeks TMZ because of fatigue.
After switch their fatigue improved. Two patients devel-
oped PCP infections before routine monitoring of CD4?
counts, none of the monitored patients (who received PCP
prophylaxis with cotrimoxazol in case CD4? counts
decreased below 0.2*109/l) developed a PCP infection.
Data from available phase 2 trials investigating ddTMZ in
gliomas indicate a high incidence of lymphopenia, espe-
cially in patient treated with the 3 weeks on/1 week off
regimen [12, 14, 16, 17, 27]. In melanoma patients treated
with daily TMZ for 6 weeks out of every 8-week cycle, a
high incidence of lymphopenia and an increased risk of
opportunistic infections were reported [28]. Clearly,
patients who receive ddTMZ are at risk to develop Pneu-
mocystis carinii pneumonia, and prophylaxis is indicated in
patients who develop lymphopenia or low CD4? counts.
Although this study has a limited number of patients and
is retrospective, it however seems from these results that
ddTMZ is an effective treatment for patients with a
recurrence of GBM or otherwise heavily pre-treated glio-
mas, albeit with an increase in toxicity. Whether it is more
effective than the standard 5 of 28-day regimen remains
unclear.
Although administration of ddTMZ regimens causes
more pronounced depletion of MGMT in peripheral blood
mononuclear cells [9], the effects of ddTMZ on MGMT
activity in brain tumor tissue and its impact on clinical
outcome remain unclear. A study from the United King-
dom, comparing standard day 1–5 every 4 weeks TMZ
with a ddTMZ schedule, (given in a 3 weeks on/1 week off
schedule) failed to show any benefit of ddTMZ in high-
grade glioma recurrent after RT only in comparison to the
standard day 1–5 every 4 weeks schedule [29]. Of note,
although these patients were chemotherapy naı¨ve, one may
assume that two-thirds of patients would have an unme-
thylated MGMT promoter. Thus, if ddTMZ would have
been effective in overcoming that resistance, one would
expect at least some trend toward a more favorable
outcome in ddTMZ treated patients. The recently reported
RTOG 0525 trial on newly diagnosed GBM also failed to
produce superior outcome of ddTMZ in newly diagnosed
GBM (and regardless of the MGMT promoter status) [30].
This casts further doubt on the usefulness of intensified
dosing regimen. Future trials into ddTMZ regimens require
a control arm with a standard dosing regimen.
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